Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1700 of 4090 results for patient

  1. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (TA1139)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults.

  2. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]

    In development Reference number: GID-TA11649 Expected publication date:  14 October 2026

  3. Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

    Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

  4. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

    Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

  5. Lyme disease (NG95)

    This guideline covers diagnosing and managing Lyme disease. It aims to raise awareness of when Lyme disease should be suspected and ensure that people have prompt and consistent diagnosis and treatment. It does not cover preventing Lyme disease.

  6. Digital technologies to support self-management of asthma: early value assessment

    In development Reference number: GID-HTE10063 Expected publication date:  05 May 2026

  7. Shoulder resurfacing arthroplasty (HTG227)

    Evidence-based recommendations on shoulder resurfacing arthroplasty. This involves reshaping the upper arm bone and placing an artificial shoulder joint onto it.

  8. Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.

  9. Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (HTG495)

    Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers.

  10. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

    Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults.

  11. Stage 1: referral points

    Referral points to virtual wards are similar to traditional models of care. Our guidance and advice can help you decide where to provide care and what to consider.

  12. Laparoscopic partial nephrectomy (HTG97)

    Evidence-based recommendations on laparoscopic partial nephrectomy. This involves making small ‘keyhole’ openings, either in the back or in the abdomen, to remove the section of kidney that contains the tumour.

  13. Laparoscopic cryotherapy for renal cancer (HTG271)

    Evidence-based recommendations on laparoscopic cryotherapy for renal cancer. This involves inserting a surgical instrument (cryoprobe) to apply freezing temperatures to the tumour and destroy the cancer cells.

  14. Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) (HTG544)

    Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the ARCHITECT and ALINITY i Urine NGAL assays, BioPorto NGAL test and NephroCheck test.

  15. Fungitell for antifungal treatment stratification (MIB118)

    NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .

  16. Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)

    Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  17. Laparoscopic gastrectomy for cancer (HTG172)

    Evidence-based recommendations on laparoscopic gastrectomy for cancer. This involves partial or total removal of the stomach to take out the tumour and affected lymph nodes through small cuts in the abdomen (keyhole surgery).

  18. Peptest for diagnosing gastro‑oesophageal reflux (MIB31)

    NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux

  19. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development Reference number: GID-TA11023 Expected publication date: TBC

  20. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]

    In development Reference number: GID-TA11340 Expected publication date: TBC

  21. CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes (MIB48)

    NICE has developed a medtech innovation briefing (MIB) on the CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes .

  22. Our charter

    An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.

  23. Entecavir for the treatment of chronic hepatitis B (TA153)

    Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.

  24. Implantation of multifocal (non-accommodative) intraocular lenses during cataract surgery (HTG170)

    Evidence-based recommendations on the implantation of multifocal (non-accommodative) intraocular lenses during cataract surgery. This involves replacing the clouded lens with an artificial one with areas of different focusing power to allow near and distant objects to be seen.

  25. Therapeutic sialendoscopy (HTG140)

    Evidence-based recommendations on therapeutic sialendoscopy. This involves using a flexible tube to enter the salivary gland, and visualise and remove the stone.

  26. Managing medicines in care homes (SC1)

    This guideline covers good practice for managing medicines in care homes. It aims to promote the safe and effective use of medicines in care homes by advising on processes for prescribing, handling and administering medicines. It also recommends how care and services relating to medicines should be provided to people living in care homes.

  27. Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse (HTG445)

    Evidence-based recommendations on uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse in women. This involves attaching mesh from the uterus or cervix either to the bone at the base of the spine or to a ligament in the pelvis to hold the uterus in place.

  28. Relugolix for treating hormone-sensitive prostate cancer (TA995)

    Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.

  29. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

    NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .

  30. Intrapartum care (NG235)

    This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.

  31. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

    Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.

  32. Implantation of accommodating intraocular lenses for cataract (HTG134)

    Evidence-based recommendations on implantation of accommodating intraocular lenses for cataract. This involves removing the clouded natural lens of the eye and replacing it with an accommodating lens to allow focusing on near and distant objects.

  33. Mini-incision surgery for total knee replacement (HTG220)

    Evidence-based recommendations on mini-incision surgery for total knee replacement. This involves using specially designed instruments to replace the knee using a smaller incision.

  34. Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (TA895)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.

  35. Sternal Talon for sternal closure in cardiothoracic surgery (MIB88)

    NICE has developed a medtech innovation briefing (MIB) on the Sternal Talon for sternal closure in cardiothoracic surgery .

  36. Padeliporfin for untreated localised prostate cancer (TA546)

    Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.

  37. Digital technologies to support monitoring of vision change at home for people with age-related macular degeneration: early use assessment

    In development Reference number: GID-HTE10073 Expected publication date:  15 September 2026

  38. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    In development Reference number: GID-TA11509 Expected publication date:  24 February 2027

  39. Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

    Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

  40. Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (TA1036)

    Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.

  41. Coil embolisation of ruptured intracranial aneurysms (HTG64)

    Evidence-based recommendations on coil embolisation of ruptured intracranial aneurysms. This involves passing a thin tube through the body to place coils inside the aneurysm.

  42. RenalSense Clarity RMS for acute kidney injury (MIB256)

    NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .

  43. Caris Molecular Intelligence for guiding cancer treatment (MIB120)

    NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .

  44. Laser correction of refractive error following non-refractive ophthalmic surgery (HTG256)

    Evidence-based recommendations on laser correction of refractive error following non-refractive ophthalmic surgery. This involves changing the shape of the cornea, so that light rays are more precisely directed onto the retina.

  45. Axxent electronic brachytherapy system for early stage breast cancer (MIB76)

    NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer

  46. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

  47. Adrenal insufficiency: identification and management (NG243)

    This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.